Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Superficial parasternal intercostal plane block with ropivacaine versus placebo for opioid exposure after cardiac surgery (EPOCH CardioLink-10): a multicentre, double-blind, randomised trial.

Lancet regional health. Americas·2026
Same author

Superficial intercostal plane blocks for post-sternotomy pain control rationale and design for the EPOCH CardioLink-10 randomized clinical trial.

Current opinion in cardiology·2026
Same author

Heart transplantation in the GLP-1 Era: Time to catch up? Invited commentary for "The association between glucagon-like peptide 1 receptor agonist therapy and outcomes after heart transplant".

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Sutureless aortic valves: timing, technique, and evidence.

Current opinion in cardiology·2026
Same author

Workflow-based Framework to Aid with High-Definition Intravascular Ultrasound-Optimised Coronary Stenting: Introducing IVUS 123 Essentials.

Interventional cardiology (London, England)·2026
Same author

Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled.

JACC. Advances·2026

Related Experiment Video

Updated: Jul 8, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Viability testing for guiding revascularization in ischemic cardiomyopathy.

Kevin Y Li1, Nitish K Dhingra1, Raumil Patel2

  • 1Division of Cardiovascular Surgery.

Current Opinion in Cardiology
|July 6, 2026
PubMed
Summary
This summary is machine-generated.

Myocardial viability testing may not predict outcomes after revascularization. Scar quantification, not viability, appears to be a stronger predictor of adverse events in ischemic cardiomyopathy.

Keywords:
cardiac imagingischemic cardiomyopathymyocardial viabilityrevascularizationscar burden

More Related Videos

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

Related Experiment Videos

Last Updated: Jul 8, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

Area of Science:

  • Cardiology
  • Cardiac Imaging
  • Interventional Cardiology

Background:

  • Myocardial viability testing traditionally guides revascularization in ischemic cardiomyopathy, assuming viable tissue predicts recovery and survival.
  • Recent trials challenge this assumption, necessitating a re-evaluation of viability testing's role with modern therapies.

Purpose of the Study:

  • To re-evaluate the clinical utility of myocardial viability testing in ischemic cardiomyopathy.
  • To assess the impact of contemporary revascularization strategies and guideline-directed medical therapy on viability testing's role.

Main Methods:

  • Review of recent clinical trials (STICH, REVIVED-BCIS2) and imaging substudies.
  • Analysis of prognostic predictors, including scar burden versus myocardial viability.

Main Results:

  • STICH trial: Coronary Artery Bypass Grafting (CABG) improved survival independently of viability status or ejection fraction improvement.
  • REVIVED-BCIS2: Percutaneous Coronary Intervention (PCI) did not improve survival even in patients with demonstrated viability.
  • Scar burden, not viability, emerged as the strongest predictor of adverse outcomes.

Conclusions:

  • Myocardial viability should be viewed as a continuous spectrum, not a binary state.
  • Scar quantification, especially via late gadolinium enhancement cardiac magnetic resonance (CMR), offers greater prognostic value than viability detection alone.
  • Further trials are needed to define the role of viability-guided revascularization with modern treatments.